Allogene Therapeutics, Inc. (NASDAQ:ALLO) Shares Bought by Lynx1 Capital Management LP

Lynx1 Capital Management LP boosted its stake in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) by 75.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,874,723 shares of the company's stock after purchasing an additional 4,672,349 shares during the quarter. Allogene Therapeutics makes up 8.7% of Lynx1 Capital Management LP's investment portfolio, making the stock its 5th biggest holding. Lynx1 Capital Management LP owned approximately 5.19% of Allogene Therapeutics worth $23,163,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently added to or reduced their stakes in the company. MML Investors Services LLC purchased a new position in shares of Allogene Therapeutics during the third quarter worth about $56,000. Barclays PLC raised its stake in shares of Allogene Therapeutics by 101.5% during the 3rd quarter. Barclays PLC now owns 342,973 shares of the company's stock worth $959,000 after buying an additional 172,745 shares during the last quarter. Geode Capital Management LLC lifted its stake in Allogene Therapeutics by 14.4% in the 3rd quarter. Geode Capital Management LLC now owns 3,227,104 shares of the company's stock valued at $9,037,000 after buying an additional 407,070 shares in the last quarter. Nordea Investment Management AB raised its holdings in Allogene Therapeutics by 2.1% in the 4th quarter. Nordea Investment Management AB now owns 460,641 shares of the company's stock valued at $986,000 after acquiring an additional 9,635 shares during the last quarter. Finally, abrdn plc acquired a new position in shares of Allogene Therapeutics during the 4th quarter valued at about $776,000. Hedge funds and other institutional investors own 83.63% of the company's stock.

Insiders Place Their Bets

In related news, insider Timothy L. Moore sold 14,746 shares of Allogene Therapeutics stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $1.71, for a total transaction of $25,215.66. Following the completion of the transaction, the insider now owns 250,713 shares in the company, valued at approximately $428,719.23. This trade represents a 5.55 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO David D. Chang sold 46,668 shares of Allogene Therapeutics stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $1.96, for a total value of $91,469.28. Following the transaction, the chief executive officer now owns 5,276,569 shares of the company's stock, valued at $10,342,075.24. This represents a 0.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 87,268 shares of company stock valued at $159,584 in the last quarter. 24.30% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of research firms recently issued reports on ALLO. HC Wainwright dropped their target price on shares of Allogene Therapeutics from $9.00 to $8.00 and set a "buy" rating for the company in a research report on Wednesday, March 19th. Citizens Jmp raised shares of Allogene Therapeutics from a "market perform" rating to an "outperform" rating and set a $5.00 price target for the company in a report on Friday, March 14th. Royal Bank of Canada reiterated an "outperform" rating and issued a $10.00 price objective on shares of Allogene Therapeutics in a research report on Friday, March 14th. Finally, Canaccord Genuity Group reiterated a "buy" rating and set a $14.00 price objective on shares of Allogene Therapeutics in a research report on Friday, March 14th. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $9.29.

Allogene Therapeutics Trading Up 2.1 %

NASDAQ ALLO traded up $0.04 on Friday, hitting $1.73. 1,204,385 shares of the company were exchanged, compared to its average volume of 3,203,518. Allogene Therapeutics, Inc. has a 1-year low of $1.23 and a 1-year high of $3.78. The company has a market cap of $374.78 million, a P/E ratio of -1.11 and a beta of 0.99. The firm has a 50 day moving average of $1.65 and a two-hundred day moving average of $2.03.

Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) last posted its earnings results on Thursday, March 13th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.06. Research analysts anticipate that Allogene Therapeutics, Inc. will post -1.28 EPS for the current fiscal year.

Allogene Therapeutics Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).